Citations

Clear

56 citation(s) found for "Mathai, S C".

Comprehensive echocardiographic evaluation of the right heart in patients with pulmonary vascular diseases: the PVDOMICS experience
Jellis, Christine , Park, Margaret , Abidov, Aiden , Jiwon, Kim, Kwon, Deborah , Maron, Bradley A. , Mathai, Stephen C. , Rischard, Franz , Vanderpool, Rebecca , Thomas, James D. , Group, the PVDOMICS Study, Jellis, Christine L , Frantz, Robert, Karas, Maria G , Rischard, Franz P , Vanderpool, Rebecca R , Mathai, Stephen C , Borlaug, Barry A. , Brittain, Evan L , Frantz, Robert P. , Hassoun, Paul M. , Horn, Evelyn M. , Jaber, Wael A. , Jiwon, Kim, Karas, Maria , Leopold, Jane A. , Mehra, Reena , Rosenzweig, Erika B. , Tang, W.H. Wilson , Group, the PVDOMICS Study

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | March 24, 2021 | Volume: 23 | Issue: 7 | Pages: 958-969

10.1093/ehjci/jeab065 | PMID 34097027 Get It

Abstract Aims There is a wide spectrum of diseases associated with pulmonary hypertension, pulmonary vascular remodelling, and right ventricular dysfunction. The NIH-sponsored PVDOMICS network seeks to perform comprehensive clinical phenotyping and endophenotyping across these disorders to further evaluate and define pulmonary vascular disease. Methods and results Echocardiography represents the primary non-invasive method to phenotype cardiac anatomy, function, and haemodynamics in these complex patients. However, comprehensive right heart evaluation requires the use of multiple echocardiographic parameters and optimized techniques to ensure optimal image acquisition. The PVDOMICS echo protocol outlines the best practice approach to echo phenotypic assessment of the right heart/pulmonary artery unit. Conclusion Novel workflow processes, methods for quality control, data for feasibility of measurements, and reproducibility of right heart parameters derived from this study provide a benchmark frame of reference. Lessons learned from this protocol will serve as a best practice guide for echocardiographic image acquisition and analysis across the spectrum of right heart/pulmonary vascular disease.
Pulmonary hypertension due to interstitial lung disease or chronic obstructive pulmonary disease: a patient experience study of symptoms and their impact on quality of life
DuBrock, Hilary M. , Nathan, Steven D. , Mathai, Stephen C. , Classi, Peter, Nelsen, Andrew C. , Olayinka‐Amao, Bimpe, Norcross, Lindsey , Martin, Susan , Martin, Susan A , DuBrock, Hilary M , Mathai, Stephen C , Reeve, Bryce B. , Kolaitis, Nicholas A

Mayo Clinic

Pulmonary Circulation | March 16, 2021 | Volume: 11 | Issue: 2 | Pages: 1-9

10.1177/20458940211005641 | PMID 33868642 Get It

Pulmonary hypertension resulting from chronic lung disease such as chronic obstructive pulmonary disease and interstitial lung disease is categorized by the World Health Organization as Group 3 pulmonary hypertension. To identify the symptoms and impacts of World Health Organization Group 3 pulmonary hypertension and to capture data related to the patient experience of this disease, qualitative research interviews were undertaken with 3 clinical experts and 14 individuals with pulmonary hypertension secondary to chronic obstructive pulmonary disease or interstitial lung disease. Shortness of breath, fatigue, cough, and swelling were the most frequently reported symptoms of pulmonary hypertension due to chronic obstructive pulmonary disease or interstitial lung disease, and shortness of breath was further identified as the single most bothersome symptom for most patients (71.4%). Interview participants also described experiencing a number of impacts related to pulmonary hypertension and pulmonary hypertension symptoms, including limitations in the ability to perform activities of daily living and impacts on physical functioning, family life, and social life as well as emotional impacts, which included frustration, depression, anxiety, isolation, and sadness. Results of these qualitative interviews offer an understanding of the patient experience of pulmonary hypertension due to chronic obstructive pulmonary disease or interstitial lung disease, including insight into the symptoms and impacts that are most important to patients in this population. As such, these results may help guide priorities in clinical treatment and assist researchers in their selection of patient‐reported outcome measures for clinical trials in patients with pulmonary hypertension due to chronic obstructive pulmonary disease or interstitial lung disease.
Obesity in Pulmonary Arterial Hypertension. The Pulmonary Hypertension Association Registry
Min, Jeff , Feng, Rui, Badesch, David , Berman-Rosenzweig, Erika, Burger, Charles, Chakinala, Murali, Marco, T De, Feldman, Jeremy, hemnes, anna, Horn, E M, Mathai, Stephen, McConnell, John W., Presberg, K, Robinson, J., Sager, Jeffrey, Shlobin, Oksana, Thenappan, Thenappan , Ventetuolo, C E, Al‐Naamani, Nadine , Mathai, Stephen C. , Ventetuolo, Corey E. , Thenappan, Thenappan , Ventetuolo, Corey E , Al-Naamani, Nadine , Mathai, Stephen C , Feng, Rui , Rosenzweig, Erika B. , Feldman, Jeremy, Hemnes, Anna R. , Lammi, Matthew R. , McConnell, John W., Presberg, Kenneth W., Sager, Jeffrey S., Shlobin, Oksana A. , Simon, Marc

Mayo Clinic

Annals of the American Thoracic Society | October 21, 2020 | Volume: 18 | Issue: 2 | Pages: 229-237

10.1513/annalsats.202006-612oc | PMID 33085915 Get It

Abstract Rationale Obesity is associated with pulmonary arterial hypertension (PAH), but its impact on outcomes such as health-related quality of life (HRQoL), hospitalizations, and survival is not well understood. Objectives To assess the effect of obesity on HRQoL, hospitalizations, and survival in patients with PAH. Methods We performed a cohort study of adults with PAH from the Pulmonary Hypertension Association Registry, a prospective multicenter registry. Multivariate linear mixed-effects regression was used to examine the relationship between weight categories and HRQoL using the Short Form-12 and emPHasis-10. We used multivariable negative binomial regression to estimate hospitalization incidence rate ratios (IRRs) and Cox regression to estimate hazard ratios (HRs) for transplant-free survival by weight status. Results A total of 767 subjects were included (mean age of 57 years, 74% female, 33% overweight, and 40% with obesity), with median follow-up duration of 527 days. Overweight patients and patients with obesity had higher baseline emPHasis-10 scores (worse HRQoL), which persisted over time (P < 0.001). Patients who are overweight and obese have a trend toward increased incidence of hospitalizations compared with normal-weight patients (IRR, 1.34; 95% confidence interval [95% CI], 0.94–1.92 and IRR, 1.33; 95% CI 0.93–1.89, respectively). Overweight patients and patients with obesity had lower risk of transplant or death compared with normal-weight patients (HR, 0.45; 95% CI, 0.25–0.80 and HR, 0.39; 95% CI, 0.22–0.70, respectively). Conclusions In a large multicenter, prospective cohort of PAH, patients who were overweight or obese had worse disease-specific HRQoL despite better transplant-free survival compared with normal-weight patients. Future interventions should address the specific needs of these patients.
Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry
Zamanian, Roham T. , Pérez, Vinicio A. de Jesús, Badesch, David B., Benza, Raymond L. , Chakinala, Murali M. , Elwing, Jean , Feldman, Jeremy, Mathai, Stephen C. , McConnell, John W., Presberg, Kenneth W., Robinson, Jeffrey C. , Sager, Jeffrey S., Shlobin, Oksana A. , Glidden, David V. , Singer, Jonathan P. , Marco, Teresa De , Kolaitis, Nicholas A , Singer, Jonathan P , Benza, Raymond L. , Mathai, Stephen C , Burger, Charles D. , Lammi, Matthew R. , Simon, Marc A. , Kawut, Steven M.

Mayo Clinic

Annals of the American Thoracic Society | October 16, 2020 | Volume: 18 | Issue: 4 | Pages: 613-622

10.1513/annalsats.202007-774oc | PMID 33064950 Get It

Abstract Rationale Single-center studies demonstrated that methamphetamine use is associated with pulmonary arterial hypertension (Meth-APAH). We used the Pulmonary Hypertension Association Registry to evaluate the national distribution of Meth-APAH and to compare its impact on patient-reported and clinical outcomes relative to idiopathic PAH. Objectives To determine if patients with Meth-APAH differ from those with idiopathic PAH in demographics, regional distribution in the United States, hemodynamics, health-related quality of life, PAH-specific treatment, and health care use. Methods The Pulmonary Hypertension Association Registry is a U.S.-based prospective cohort of patients new to care at a Pulmonary Hypertension Care Center. The registry collects baseline demographics, clinical parameters, and repeated measures of health-related quality of life, World Health Organization functional class, 6-minute walk distance, therapy, and health care use. Repeated measures of functional class, health-related quality of life, type of therapy, emergency department visits, and hospitalizations were compared using generalized estimating equations. Results Of 541 participants included, 118 had Meth-APAH; 83% of Meth-APAH arose in the western United States. The Meth-APAH group was younger and had a poorer socioeconomic status and lower cardiac index than the idiopathic PAH group, despite no difference in mean pulmonary artery pressure or pulmonary vascular resistance. The Meth-APAH group had a more advanced functional class in longitudinal models (0.22 points greater; 95% confidence interval [CI], 0.07 to 0.37) and worse PAH-specific (emPHasis-10) health-related quality of life (−5.4; 95% CI, −8.1 to −2.8). There was no difference in dual combination therapy; however, participants with Meth-APAH were less likely to be initiated on triple therapy (odds ratio [OR], 0.43; 95% CI, 0.24 to 0.77) or parenteral therapy (OR, 0.10; 95% CI, 0.04 to 0.24). Participants with Meth-APAH were more likely to seek care in the emergency department (incidence rate ratio, 2.30; 95% CI, 1.71 to 3.11) and more likely to be hospitalized (incidence rate ratio, 1.42; 95% CI, 1.10 to 1.83). Conclusions Meth-APAH represents a unique clinical phenotype of PAH, most common in the western United States. It accounts for a notable proportion of PAH in expert centers. Assessment for methamphetamine use is necessary in patients with PAH.
Hospitalization in Connective Tissue Disease Associated Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry
Mullin, Christopher J., Shlobin, Oksana A. , Elwing, Jean , Mathai, S.C. , Lammi, Matthew R. , Benza, Raymond L. , Burger, Charles D. , Simon, Marc A. , Ventetuolo, Corey E.

Mayo Clinic

B55. POT POURRI OF THE TOP CLINICAL STUDIES IN PULMONARY HYPERTENSION | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A3788-A3788

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3788 Get It

Quality of Life of Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Idiopathic Pulmonary Arterial Hypertension (IPAH): The Pulmonary Hypertension Association Registry (PHAR)
Narasimmal, S.P., Pugliese, Steven C. , Bull, Todd M., Marco, Teresa De , McConnell, J.W. , Feldman, Jeremy P., Sager, Jeffrey S., Badesch, David B., Ryan, John , Grinnan, D. , Zwicke, Dianne, Elwing, Jean , Robinson, Jeffrey C. , Moss, James , Eggert, Michael, Shlobin, Oksana A. , Bartolome, Sonja, Mathai, S.C. , Mazimba, Sula , Lammi, Matthew R. , Thenappan, Thenappan , Horn, Evelyn M. , Frantz, Robert P. , Al‐Naamani, Nadine

Mayo Clinic

C104. LATEST CLINICAL INVESTIGATIONS IN ACUTE AND CHRONIC THROMBOEMBOLISM DISORDERS OF THE PULMONARY CIRCULATION | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A6048-A6048

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6048 Get It

Health Disparities and Treatment Patterns in Portopulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension: An Analysis of the Pulmonary Hypertension Association Registry
Bartolome, Sonja, Feldman, Jeremy P., Sager, Jeffrey S., Presberg, Kenneth W., Mathai, S.C. , Klinger, James R. , Eggert, Michael, Robinson, Jeffrey C. , Fineman, Jeff, Marco, Teresa De , Elwing, Jean , Badesch, David B., Bull, Todd M., Cadaret, Linda , Ramani, Gautam , Ford, H. James , Mazimba, Sula , Runo, James , Chakinala, Murali M. , Ryan, John , Grinnan, D. , Krowka, Michael J. , DuBrock, Hilary M. , Burger, Charles D. , Rosenzweig, Erika B. , Lammi, Matthew R. , Thenappan, Thenappan , Al‐Naamani, Nadine , Simon, Marc A. , Horn, Evelyn M. , Frantz, Robert P.

Mayo Clinic

B27. UP-TO-DATE PAH ASSESSMENT AND MANAGEMENT | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A2906-A2906

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2906 Get It

Intersecting Identities and Patient Outcomes in Pulmonary Arterial Hypertension: Early Results in Derivation of a Model Using the Pulmonary Hypertension Association Registry (PHAR)
Grinnan, D. , Kang, Le , DeWilde, Christine , Johnson, D. , Allen, Roblee P., Badesch, David B., Bartolome, Sonja, Bull, T.M., Chakinala, Murali M. , DeMarco, Teresa , Elwing, Jean , Feldman, Jeremy P., Ford, H. James , Klinger, James R. , Mathai, S.C. , McConnell, J.W. , Presberg, Kenneth W., Ramani, Gautam , Robinson, Jeffrey C. , Runo, James , Sager, Jeffrey S., Shlobin, Oksana A. , Zamanian, R.T., Benza, Raymond L. , Burger, Charles D. , Frantz, Robert P. , Hemnes, Anna R. , Horn, Evelyn M. , Lammi, Matthew R. , Rosenzweig, Erika B. , Simon, Marc A. , Thenappan, Thenappan , Ventetuolo, Corey E. , Williamson, Timothy L.

Mayo Clinic

C52. USE YOUR ILLUSION II: CLINICAL RESEARCH IN PAH | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A5098-A5098

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5098 Get It

Increasing Age Is Associated with Worsening Physical Function Despite More Favorable Cardiopulmonary Hemodynamics: A Pulmonary Hypertension Association Registry (PHAR) Report
Kime, Noah , Bartolome, Sonja, Badesch, David B., Bull, Todd M., Chakinala, Murali M. , Elwing, Jean , Feldman, Jeremy P., Fineman, Jeffrey R. , Grinnan, D. , Mathai, S.C. , McConnell, J.W. , Presberg, Kenneth W., Robinson, Jeffrey C. , Sager, Jeffrey S., Shlobin, Oksana A. , Zamanian, Roham T. , Marco, Teresa De , Investigators, PHAR, DesJardin, Jacqueline T. , Kolaitis, Nicholas A , Kronmal, Richard A. , Benza, Raymond L. , Rosenzweig, Erika B. , Burger, Charles D. , Horn, Evelyn M. , Lammi, Matthew R. , Simon, Marc A. , Thenappan, Thenappan

Mayo Clinic

A105. GLORY DAYS: THE LATEST CLINICAL RESEARCH IN PAH | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A2516-A2516

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2516 Get It